Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
The facility is expected to become operational by FY2028-29
Emcure to distribute Roche's kidney transplant and anemia drugs in India
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Subscribe To Our Newsletter & Stay Updated
